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Abstract
Background: Combined inhibition of complement and leukocyte adhesion by sCR1sLeX reduces lung allograft dysfunction up to 24 h. In
the present study its effect on graft function and acute rejection was evaluated up to 5 days after experimental transplantation. Methods:
Orthotopic single left lung transplantation was performed in 35 male rats (Brown Norway to Fischer 344) after a total ischemic time of 20 h.
Two groups were assessed after 1, 3, and 5 days post-transplant, respectively (n ¼ 5 per group and time point): controls vs. recipients which
received 10 mg/kg sCR1sLeX 15 min prior to reperfusion. In addition, five animals received 10 mg/kg per day sCR1sLeX for 5 days. For
blood gas analysis of the graft, the contralateral lung was occluded for 5 min to assess graft function. Lung grafts were flushed, and
histological grading was performed in blinded fashion according to the International Society for Heart and Lung Transplantation criteria.
Results: Graft PaO2 in recipients treated with sCR1sLe
X was superior on day 1 (383 ^ 118 vs. 56 ^ 15 mmHg; P , 0:0001) and day 3
(446 ^ 48 vs. 231 ^ 108 mmHg; P , 0:0001). Five days after transplantation, no difference in PaO2 was found (61 ^ 28 vs. 83 ^ 31 mmHg;
P ¼ 0:59). Repeated treatment with sCR1sLeX for 5 days did not improve PaO2 (64 ^ 5 mmHg; P ¼ 0:65 vs. control; P ¼ 0:93 vs.
sCR1sLeX). At any time point, there was no difference in the degree of rejection between groups. Conclusions: In this model sCR1sLeX
provided marked improvement of graft function up to 3 days, but inhibition of both complement system and selectin dependent leukocyte
adhesion failed to protect against acute rejection. q 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Lung transplantation has become an established therapeu-
tic option for end-stage pulmonary disease. Ischemia and
reperfusion injury remains the major problem in the early
phase after lung transplantation. Both severe reperfusion
injury and acute rejection episodes may predispose to
chronic graft rejection, i.e. obliterative bronchiolitis.
Improved preservation and the flushing technique have
reduced morbidity of early graft dysfunction, however,
severe ischemia–reperfusion injury still occurs in about
10% of lung transplant recipients.
The pathophysiology of ischemia–reperfusion injury has
been extensively studied. Therapeutic strategies of blocking
only one of the redundant pathways of the nonspecific
immune response have shown limited success [1]. There-
fore, the modulation of more than one pathway of ischemia–
reperfusion injury seems to be a promising strategy.
Recently, the glycoprotein sCR1sLeX (Avant Immu-
notherapeutics, Needham, MA) has been synthesized by
post-translational glycosylation of recombinant human
soluble complement receptor type 1 (sCR1) with sialyl
Lewis X (sLeX; CD15s) in a mammal cell line [2].
sCR1sLeX combines the effects of both sCR1 and sLeX in
one molecule. sCR1 is the most potent known inhibitor of
the three complement pathways [3]. sLeX is a terminal
component of oligosaccharides on many glycoproteins and
glycolipids on leukocytes and endothelial cells and a chief
ligand common to all selectins. Its biological potential has
been shown by a dramatic reduction of lung injury after
intravenous infusion of cobra venom factor, an injury that
is dependent on neutrophils, oxygen radicals, and P-selectin
[4], and its effectiveness has been confirmed in further lung
injury models [5]. sCR1sLeX reduced myocardial infarct
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size [6] and neutrophil infiltration in acute lung injury
models in vivo [7] as well as infarct size and consecutive
neurologic deficit in experimental stroke in mice. Its effect
has been demonstrated not only when sCR1sLeX has been
given as pretreatment, but also when the drug has been
administered after the onset of ischemia [8]. In these models
sCR1sLeX was superior to sCR1 in several aspects.
The aim of this study was to evaluate the effect of
sCR1sLeX on post-transplant graft function in a rat model
of left lung allotransplantation of major immunological
mismatch after prolonged ischemia in comparison with
untreated controls. The extent of immunological protection
was specifically addressed by this study design, as in
patients such combination of reperfusion injury and immu-
nological mismatch is usually combined and therefore of
high clinical relevance. Furthermore, continuous daily treat-
ment was compared to single drug application before reper-
fusion.
2. Materials and methods
Weight matched (200–250 g) male Fischer F344 rats
received orthotopic single left lung allografts from male
Brown Norway rats. A cuff technique for the vessel anasto-
moses and a conventional running suture for the bronchial
anastomosis were applied. All animals received humane
care in compliance with the European Convention of
Animal Care. The protocol was approved by the local
animals study committee.
2.1. Donor procedure
Animals were anesthetized by intraperitoneal administra-
tion of pentobarbital (50 mg/kg) and heparinized (500 IU/
kg). A tracheotomy was carried out and the animals were
ventilated through a cannula (FiO2 ¼ 1:0) by a Harvard
rodent ventilator (Harvard Apparatus, South Natick, MA)
at a tidal volume of 10 ml/kg. After division of the inferior
vena cava and resection of the left appendix of the heart, a
small silicon tube was inserted into the main pulmonary
artery. Both lungs were flushed with 20 ml of LPD solution
(Perfadexw, Xvivo, Go¨teborg, Sweden) at a pressure of 20
cm H2O. The trachea was tied in end-inspiration. The heart–
lung block was removed and 14 gauge cuffs were placed
around the pulmonary artery and vein. The vessels were
inverted and tied onto the cuff. The lung was stored in
LPD solution at 4 8C until implantation.
2.2. Recipient procedure
Transplantation was performed after 20 h of cold ische-
mia at 4 8C. The recipient was anesthetized by breathing
Halothane in a glass chamber followed by intubation.
Anesthesia was maintained with Halothane 2%. A left
lateral thoracotomy was performed in the 4th intercostal
space. The left hilum was dissected. After clamping the
pulmonary artery and vein with removable microvascular
clips, the pulmonary vein was opened, flushed with hepar-
inized saline solution, and the cuff was inserted and fixed
with 6-0 Silk. In the same technique, the pulmonary artery
was anastomosed. The native left lung was removed and the
bronchial anastomosis performed with a running over-and-
over suture with 9-0 Monosofw (Tyco Healthcare, Wollerau,
Switzerland). The lung was first reventilated and then reper-
fused. A chest tube was inserted and the thoracotomy
closed. The chest tube was removed after restoration of
spontaneous breathing.
2.3. Assessment
The recipient animal was anesthetized by intraperitoneal
administration of pentobarbital (50 mg/kg) and ventilated
with an FiO2 of 1.0, a frequency of 100/min and a tidal
volume of 8 ml/kg by a tracheotomy. For functional assess-
ment of the transplanted left lung, the right hilum was
dissected and the right pulmonary artery and the right
main bronchus were occluded with microvascular clips.
Five minutes after occlusion, a steady state was reached
and an arterial blood gas sample was drawn from the thor-
acic aorta which was assessed with a blood gas analyzer
(AVL 993, AVL List GmbH, Graz, Austria). After hepar-
inization with 500 IU/kg, the microvascular clips were
removed and the lungs were flushed with 20 ml saline solu-
tion through the pulmonary artery. The heart–lung block
was excised and the lungs were fixed overnight at room
temperature with 10% buffered formalin. Formalin was
instilled through a tube inserted in the trachea to expand
the lungs with a defined pressure of 20 cm H2O. The trans-
planted left lung and the native right lung were then sepa-
rately embedded in paraffin, and slides of 4 mm thickness
were stained with hematoxylin–eosin. The slides were rated
by a lung pathologist in blinded fashion according to the
criteria of the International Society for Heart and Lung
Transplantation (ISHLT) [9].
2.4. Study groups
In each group five animals were transplanted for each
time interval until harvest, i.e. days 1, 3 and 5, respectively.
In treated animals, recipients received 10 mg/kg sCR1sLeX
15 min prior to reperfusion by intracardiac injection. In
addition, five recipients were treated continuously with
daily intravenous injection of 10 mg/kg sCR1sLeX for 5
days.
2.5. Statistical analysis
For PaO2, the mean ^ standard deviation and for histolo-
gical grading, the median (range) is given. Analysis of
variance (ANOVA) with planned contrast analysis between
the groups (PaO2) and the Mann–Whitney U-test (histolo-
gical grading) were applied, respectively. The STATIS-
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TICA 5.1 software (StatSoftw, Tulsa, OK) was used. A P
value of less than 0.05 was considered significant.
3. Results
Warm ischemic time in all transplantation groups was
between 20.0 ^ 0.71 and 20.8 ^ 1.30 min, with no signifi-
cant difference between groups.
Four recipients in the control group and one animal trea-
ted with sCR1sLeX suffered from severe edema with aspira-
tion to the contralateral side and died within the first 3 h
after transplantation. In addition, one recipient died due to
technical problems regarding the bronchial anastomosis. All
these animals were excluded from analysis, and further
transplantations were carried out.
3.1. Blood gas analysis
Twenty-four hours after reperfusion, PaO2 was very low
in control animals (56 ^ 15 mmHg). Treatment with
sCR1sLeX resulted in superior graft function compared to
controls (383 ^ 118 mmHg; P , 0:0001; Fig. 1).
A further improvement in PaO2 was noted on day 3 in
treated animals (446 ^ 48 mmHg) whereas arterial oxygen
pressure in controls was 231 ^ 109 mmHg (P , 0:0001 vs.
sCR1sLeX).
No significant difference between controls and treated
animals was observed 5 days after transplantation
(83 ^ 31 vs. 61 ^ 28 mmHg; P ¼ 0:59).
Daily treatment with sCR1sLeX for 5 days did not reveal
any improvement (64 ^ 5 mmHg) compared to either
controls on day 5 (P ¼ 0:65) or animals which received a
single dose of sCR1sLeX and were sacrificed after 5 days
(P ¼ 0:93).
Intra-group analysis in controls revealed an improvement
of PaO2 from day 1 (56 ^ 15 mmHg) to day 3 (231 ^ 109
mmHg; P , 0:0001). No significant difference was
observed between day 1 and day 5 (83 ^ 31 mmHg;
P ¼ 0:52). The superior graft function 24 h after reperfusion
in recipients treated with sCR1sLeX (383 ^ 118 mmHg)
was followed by a small increase of PaO2 on day 3
(446 ^ 48 mmHg; P ¼ 0:14). In this allograft setting,
PaO2 on day 5 in sCR1sLe
X treated animals (61 ^ 28
mmHg) was very low compared to day 1 (P , 0:0001).
3.2. Rejection grading
No difference in either perivascular or peribronchial
rejection grading between controls and treated animals
was observed at any given point in time (Table 1). In both
groups, the onset of rejection was seen already on day 3
(control: P ¼ 0:056 (perivascular), P ¼ 0:11 (peribron-
chial) vs. control day 1; sCR1sLeX group: P ¼ 0:0079 (peri-
vascular), P ¼ 0:15 (peribronchial) vs. sCR1sLeX group day
1), and significant rejection was noted 5 days after trans-
plantation (control: P ¼ 0:016 (perivascular), P ¼ 0:029
(peribronchial) vs. control day 1; sCR1sLeX group: P ¼
0:0079 (perivascular), P ¼ 0:0079 (peribronchial) vs.
sCR1sLeX group day 1).
4. Discussion
In this model of unilateral left lung allotransplantation in
rats after prolonged ischemia, inhibition of both the comple-
ment system and the selectin dependent leukocyte adhesion
by sCR1sLeX exerted prolonged protection against reperfu-
sion injury as substantiated by the transplants’ gas exchange
at days 1 and 3 after transplantation. However, no effect on
acute rejection has been observed.
A recent study by our group underlined the significant
improvement by sCR1sLeX after prolonged ischemia on
graft function at 24 h after transplantation of both gas
exchange and markers of reperfusion injury compared to
either untreated controls or recipients treated with the
complement inhibitor sCR1 alone [10].
Complement, a proteolytic cascade system, is an effector
of the non-specific and humoral immune response and a
stimulator of leukocyte activation by the complement
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Fig. 1. PaO2 (mmHg) of the isolated grafts at 1, 3, and 5 days after reperfu-
sion (open circles: control animals; black squares: sCR1sLeX).
Table 1
Rejection grading of the allografts 1, 3, and 5 days after reperfusion
Day 1 Day 3 Day 5
Vascular Airway Vascular Airway Vascular Airway
Control A0 (A0–A2) B0 (B0–B1) A2 (A1–A2) B1 (B0–B2) A3 (A2–A4) B2 (B2–B2)
sCR1sLeX A0 (A0–A2) B0 (B0–B0) A2 (A2–A2) B1 (B0–B2) A3 (A3–A3) B2 (B2–B3)
component 5a (C5a). The complement receptor type 1
(CR1; CD35; C3b/C4b receptor) is a transmembrane glyco-
protein on erythrocytes and virtually all leukocytes.
Whereas phagocytes bind particles by CR1 when they are
coated with activated complement component 3 (C3b) and
subsequently ingest them, the extracellular portion of CR1
(soluble CR1; sCR1) can be shed from neutrophils or
macrophages [3,11]. sCR1 has been shown to be the most
potent inhibitor of the classical, alternative, and lectin path-
way of complement activation with more than 100 fold
more effect than any other soluble complement regulatory
protein [3].
Ischemia–reperfusion injury has been shown to be
complement dependent, because inhibitors of complement
activation limited this type of injury, e.g. in models of rat
myocardial infarction [12], acute neutrophil dependent
inflammatory lung injury [13] or iso- and allograft trans-
plantation [14,15]. In rat lung isotransplantation, sCR1
conferred protection against lung injury. It reduced neutro-
phil infiltration, cellular deposition of C5b-9 complexes and
serum complement hemolytic activity, and improved
pulmonary vascular resistance, gas exchange and ultimately
survival [15]. In unilateral swine lung allotransplantation
after prolonged ischemia, sCR1 completely inhibited
serum complement activity and significantly reduced reper-
fusion edema [16]. The relevance of these findings has
recently been confirmed by a clinical multicenter trial
with sCR1 in lung transplant patients [17].
Moreover, complement inhibition may also reduce the
acquired immune response, as the induction of antibody
responses against T cell dependent antigens is modulated
by complement. Alloantibody response against donor-speci-
fic antigens and the proportion of activated B and T spleno-
cytes after transplantation were decreased by complement
inhibition [18], endothelial and vascular injury was reduced,
and graft survival in experimental kidney allotransplanta-
tion was prolonged [14].
Selectins are three closely related and well conserved
adhesion molecules that mediate initial leukocyte endothe-
lial interaction. They interact with fucosylated carbohydrate
ligands, especially structures containing sLeX, and are upre-
gulated in a number of different lung injuries. Specific inhi-
bitors such as monoclonal antibodies, selectin ligands [19]
or inducers of selectin shedding such as leumedins have
been studied in different models of lung transplantation.
Blockade of both leukocyte integrin adhesion molecule
and its counterpart, intercellular adhesion molecule-1
(ICAM-1), has been shown to be efficient in a rat lung
transplant model, as combined administration of monoclo-
nal antibodies against ICAM-1, CD11a and CD18 resulted
in superior gas exchange 24 h after reperfusion and reduced
neutrophil accumulation in lung tissue [20]. In addition,
blockade of P-selectin by a monoclonal anti-P-selectin anti-
body or a selectin inhibitor improved graft function and
reduced PMN infiltration after syngeneic rat lung transplan-
tation [21].
In vivo, selectin ligands are usually necessary to recruit
neutrophils to sites of inflammation, evidenced by the
congenital disorder of leukocyte adhesion deficiency
syndrome type 2 where patients are deficient of sLeX
expression [22]. sLeX is a terminal component of oligosac-
charides on many glycoproteins and glycolipids on leuko-
cytes and endothelial cells, a chief ligand common to all
selectins and therefore proved to be an attractive ‘mimic’
to inhibit selectin dependent injury [4]. Endothelial sLeX
may be upregulated in the graft endothelium within 30
min post-revascularization as recently shown in kidney
grafts [23], and administration of the sLeX analogue CY-
1503 improved gas exchange after canine lung allotrans-
plantation and reduced neutrophil influx to the graft tissue
and alveoli [24].
The glycoprotein sCR1sLeX has been synthesized by
glycosylating sCR1 with the tetrasaccharid sLeX [2], thus
maintaining the complement blocking activity of sCR1 and
furthermore blocking selectin-mediated cellular adhesion.
The main counterparts of endothelial selectins, E-and P-
selectin, are blocked, as well as the ligands of platelets P-
selectin and leukocytes L-selectin [7]. A further advantage
may be that sCR1sLeX accumulates in inflamed areas
through binding to endothelial selectins [7]. In vivo models
of experimental stroke [8], myocardial infarction [6] and
neutrophil dependent acute lung injury [7] demonstrated
that sCR1sLeX efficiently inhibited complement. In the
stroke model the administration of sCR1sLeX at the time
of reperfusion also improved outcome, albeit to a lesser
degree. Treating evolving reperfusion injury may therefore
be a promising option for clinical use of this substance.
Acute vascular rejection was uniformly histologically
observed in our model and confirmed by the severely
compromised gas exchange of the grafts in both treatment
groups as well as in the controls. Neither single shot treat-
ment on day 1, nor daily continuous treatment until day 5
reduced acute rejection in this model. This finding is in
contrast with protective effects in allotransplantation by
either blockade of complement [25] by sCR1 or of selectin
by sLeX in a similar rat lung transplant model [26]. The
substance did not reduce the primarily lymphocytic inflam-
mation of acute rejection although it reduced neutrophil
dependent ischemia–reperfusion in the utilized model. The
results suggest insufficient blocking of acute lung rejection,
e.g. insufficient dosage, or substance inactivation. There
seems to be evidence that sCR1sLeX binds to inflamed
vascular endothelium, and dosage may be inadequate for
the large inflamed surface during lung rejection. However,
the possibility that T-lymphocyte traffic during rejection is
less dependent on selectins cannot be completely excluded.
A concomitant immunosuppressive regimen might have led
to differences between treatment groups in this model of
major histocompatibility mismatch and needs further
evaluation.
In conclusion, sCR1sLeX has proven to have a remark-
able efficacy after prolonged ischemia to inhibit ischemia–
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reperfusion lung injury up to 3 days after rat lung allotrans-
plantation. Further studies should focus on its effect in
already established reperfusion injury. As a sole anti-rejec-
tion substance, sCR1sLeX, however, failed to protect against
severe acute rejection.
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